By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Thrasos Therapeutics 

86 South Street

Hopkinton  Massachusetts  01748  U.S.A.
Phone: 508-417-7202 Fax: 508-417-7212



Drug Discovery

Company News
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 3/31/2015 9:30:56 AM
Thrasos Therapeutics Announces Successful Formal Interim Analysis And Clinical Update For Phase 2 Study Of THR-184 For Acute Kidney Injury 9/16/2014 8:27:10 AM
Thrasos Therapeutics Appoints GaƩtan Gravel And Joseph Zakrzewski To Board Of Directors 8/12/2014 8:20:26 AM
Thrasos Therapeutics Appoints Donald Notman As Senior Vice President And Chief Financial Officer 6/18/2014 11:32:53 AM
Thrasos Therapeutics Presents Preclinical Data Demonstrating THR-184 Prevents Loss Of Kidney Function Following Acute Ischemic Injury 6/3/2014 9:54:32 AM
GlaxoSmithKline (GSK) Backs Thrasos Therapeutics With $35 Million for Acute Kidney Injury Tx Research 10/25/2012 7:12:09 AM
Thrasos Therapeutics and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease 2/7/2012 6:54:02 AM
Thrasos Therapeutics Appoints Dr. Andreas Orfanos as Chief Medical Officer 9/20/2011 10:10:52 AM
Thrasos Therapeutics Initiates Phase 1 Clinical Trial for THR-184 in Acute Kidney Injury 9/13/2011 10:25:43 AM
Thrasos Therapeutics Issued U.S. Patent for First-in-Class Compounds That Selectively Target Key Receptors of the Bone Morphogenetic Protein Pathway 3/3/2009 9:24:05 AM